Clinical Trials Directory

Trials / Conditions / Tongue Cancer

Tongue Cancer

53 registered clinical trials studyying Tongue Cancer5 currently recruiting.

StatusTrialSponsorPhase
RecruitingSurgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Contro
NCT07203911
Tobias TodsenN/A
RecruitingA Study of Tongue Strength and Endurance Using the Iowa Oral Performance Instrument (IOPI) Tongue Strength Tra
NCT07124520
Memorial Sloan Kettering Cancer CenterN/A
RecruitingArabic PRO Measures for Head and Neck Cancer Radiotherapy.
NCT06662929
King Saud University
UnknownSurgical Margin Assessment by 3D Ultrasound
NCT05740774
Rigshospitalet, DenmarkN/A
CompletedThe Registry of Oncology Outcomes Associated With Testing and Treatment
NCT04028479
Taproot Health
TerminatedClinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers
NCT04738786
Samsung Medical CenterN/A
CompletedDose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
NCT04430842
Quadriga Biosciences, Inc.Phase 1
WithdrawnOral Stent Device for Radiation Treatments of Oral Cancers
NCT04041141
Indiana University
CompletedUltrasound in Tongue Cancer- a Help to Decide Depth of Invasion and to Improve the Surgical Margin
NCT04059861
Region Örebro CountyN/A
CompletedStudy of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge
NCT03602079
Klus Pharma Inc.Phase 1 / Phase 2
CompletedRadiotherapy of Tongue Cancer Using an Intraoral Stent
NCT04337853
Oslo University HospitalPhase 1
CompletedQuality of Life in Patients Treated for Tongue and/or Jaw Neoplasia Before and After Speech Therapy
NCT04126226
Hospital de Clinicas de Porto AlegreN/A
SuspendedCorrelation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer
NCT03181035
Sunnybrook Health Sciences CentrePhase 1 / Phase 2
RecruitingProsthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue
NCT02584270
University of MichiganN/A
CompletedHigh-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer
NCT03008330
Fuda Cancer Hospital, GuangzhouPhase 1 / Phase 2
WithdrawnHypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcin
NCT02295540
Rutgers, The State University of New JerseyN/A
TerminatedCetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
NCT02177838
Rutgers, The State University of New JerseyN/A
CompletedCirculating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV No
NCT02245100
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
CompletedSorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell C
NCT02035527
Ohio State University Comprehensive Cancer CenterPhase 1
CompletedAcetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoi
NCT02123511
Mayo ClinicPhase 2
WithdrawnEntolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Ra
NCT01728480
Roswell Park Cancer InstitutePhase 1
WithdrawnPhotodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropha
NCT01718223
Roswell Park Cancer InstituteN/A
WithdrawnRadiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal C
NCT01953952
Radiation Therapy Oncology GroupPhase 2
TerminatedPatient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer
NCT01949740
University of Chicago
UnknownEffects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue
NCT01854021
tiejun ZhangN/A
CompletedPI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT01816984
University of ChicagoPhase 1 / Phase 2
WithdrawnBotanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiatio
NCT01674374
Roswell Park Cancer InstitutePhase 2
CompletedPaclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating
NCT01847326
University of ChicagoPhase 1
Completed18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis
NCT01806675
Sanjiv Sam GambhirPhase 1 / Phase 2
TerminatedTalactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Hea
NCT01528137
Stanford UniversityPhase 1
TerminatedA Study of Tongue Conservation Surgery for Oral Tongue Cancer
NCT03161548
Taipei Veterans General Hospital, TaiwanPhase 2
CompletedTLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squam
NCT01334177
University of WashingtonPhase 1
WithdrawnEverolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck C
NCT01332279
Fox Chase Cancer CenterPhase 1
CompletedCarboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurr
NCT01316757
Fox Chase Cancer CenterPhase 2
CompletedPhase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
NCT00939627
National Cancer Institute (NCI)Phase 2
CompletedDirect Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental
NCT01816841
Ohio State University Comprehensive Cancer CenterN/A
CompletedCetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cance
NCT01637194
Fox Chase Cancer CenterPhase 1
TerminatedSunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C
NCT00906360
National Cancer Institute (NCI)Phase 1
RecruitingTransoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
NCT01473784
Ohio State University Comprehensive Cancer CenterN/A
CompletedPhase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
NCT01469429
Ohio State University Comprehensive Cancer CenterPhase 1 / Phase 2
CompletedSaracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00513435
National Cancer Institute (NCI)Phase 2
CompletedDasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00507767
National Cancer Institute (NCI)Phase 2
CompletedFreeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral
NCT01504932
Ohio State University Comprehensive Cancer CenterN/A
CompletedErlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec
NCT00397384
National Cancer Institute (NCI)Phase 1
CompletedBortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell
NCT00103259
National Cancer Institute (NCI)Phase 2
CompletedGM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and N
NCT00293462
Marilyn DoddPhase 3
CompletedLapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00114283
National Cancer Institute (NCI)Phase 2
CompletedS0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00096512
National Cancer Institute (NCI)Phase 2
CompletedGefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can
NCT00068497
National Cancer Institute (NCI)N/A
CompletedGene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
NCT00064103
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedIxabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
NCT00033618
National Cancer Institute (NCI)Phase 2
CompletedErlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
NCT00049283
National Cancer Institute (NCI)Phase 1
CompletedBowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
NCT00330382
National Cancer Institute (NCI)Phase 2